Free Trial
NASDAQ:CAPS

Capstone Therapeutics Q2 2025 Earnings Report

Capstone Therapeutics logo
$1.24 -0.05 (-3.88%)
As of 08/15/2025 04:00 PM Eastern

Capstone Therapeutics EPS Results

Actual EPS
-$0.13
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Capstone Therapeutics Revenue Results

Actual Revenue
$12.85 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Capstone Therapeutics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Friday, August 15, 2025
Conference Call Time
7:00AM ET

Capstone Therapeutics Earnings Headlines

Michael Parker
One stock to replace Nvidia
Investing Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another to rival Tesla… and a third to upset Nvidia. These little-known stocks are poised to overtake the three reigning tech darlings in a move that could completely reorder the top dogs of the stock market. Eric Fry gives away names, tickers and full analysis in this first-ever free broadcast.
A capstone project
See More Capstone Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Capstone Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Capstone Therapeutics and other key companies, straight to your email.

About Capstone Therapeutics

Capstone Therapeutics (NASDAQ:CAPS), a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.

View Capstone Therapeutics Profile

More Earnings Resources from MarketBeat